The estimated Net Worth of Habib J Dable is at least $31.5 millió dollars as of 1 July 2021. Mr. Dable owns over 100,000 units of Acceleron Pharma Inc stock worth over $25,138,685 and over the last 8 years he sold XLRN stock worth over $2,050,736. In addition, he makes $4,273,090 as President, Chief Executive Officer és Director at Acceleron Pharma Inc.
Sign up
Mr. Dable XLRN stock SEC Form 4 insiders trading
Habib has made over 8 trades of the Acceleron Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of XLRN stock worth $3,504,000 on 1 July 2021.
The largest trade he's ever made was exercising 100,000 units of Acceleron Pharma Inc stock on 1 July 2021 worth over $3,504,000. On average, Habib trades about 8,441 units every 43 days since 2016. As of 1 July 2021 he still owns at least 140,636 units of Acceleron Pharma Inc stock.
You can see the complete history of Mr. Dable stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Habib Dable biography
Habib J. Dable is President, Chief Executive Officer, Director of the Company. Mr. Dable has served as our Chief Executive Officer and President and a member of our Board of Directors since December 2016. Mr. Dable has served as a member of the board of directors of Millendo Therapeutics, Inc. since September 2018. He is a seasoned pharmaceutical executive, with experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global product launches. Prior to joining us, Mr. Dable served in roles of increasing responsibility at Bayer AG beginning in 1994, most recently serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable earned both Bachelor’s and Master’s degrees of Business Administration from the University of New Brunswick in Canada.
What is the salary of Habib Dable?
As the President, Chief Executive Officer és Director of Acceleron Pharma Inc, the total compensation of Habib Dable at Acceleron Pharma Inc is $4,273,090. There are no executives at Acceleron Pharma Inc getting paid more.
How old is Habib Dable?
Habib Dable is 50, he's been the President, Chief Executive Officer és Director of Acceleron Pharma Inc since 2016. There are 11 older and no younger executives at Acceleron Pharma Inc. The oldest executive at Acceleron Pharma Inc is Jay Backstrom, 65, who is the Executive Vice President - Research and Development.
What's Habib Dable's mailing address?
Habib's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 S, CAMBRIDGE, MA, 02139.
Insiders trading at Acceleron Pharma Inc
Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops és Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.
What does Acceleron Pharma Inc do?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
What does Acceleron Pharma Inc's logo look like?
Complete history of Mr. Dable stock trades at Acceleron Pharma Inc, Albireo Pharma Inc, Blueprint Medicines Corp és Millendo Therapeutics
Acceleron Pharma Inc executives and stock owners
Acceleron Pharma Inc executives and other stock owners filed with the SEC include:
-
Habib Dable,
President, Chief Executive Officer, Director -
Kevin McLaughlin,
Chief Financial Officer, Senior Vice President, Treasurer -
Sujay Kango,
Executive Vice President and Chief Commercial Officer -
Ravindra Kumar,
Senior Vice President, Chief Scientific Officer -
Francois Nader,
Independent Chairman of the Board -
Joseph Zakrzewski,
Independent Director -
Terrence Kearney,
Independent Director -
Thomas McCourt,
Independent Director -
Karen Smith,
Independent Director -
Todd James,
Senior Vice President Corporate Affairs and Investor Relations -
Kemal Malik,
Independent Director -
Christopher Hite,
Director -
Laura Hamill,
Director -
Jay Backstrom,
Executive Vice President - Research and Development -
Terrance Mcguire,
Director -
Tom Maniatis,
Director -
Jean George,
Director -
John L Knopf,
CEO and President -
Steven D Ertel,
SVP & Chief Business Officer -
Matthew L Sherman,
SVP & Chief Medical Officer -
Richard F Pops,
Director -
Adam M Veness,
SVP, General Counsel and Sec. -
John D Quisel,
EVP, Chief Business Officer -
Christopher Rovaldi,
SVP, Program Mgmt and Ops -
Robert K Zeldin,
EVP & Chief Medical Officer -
Corp /De/ Celgene,
10% owner -
Anthony B Evnin,
Director -
Edwin M Jr Kania,
Director -
Venture Management Co Iv Ll...,
-
Venture Management Co Iv Ll...,
-
Advisors Llcorbimed Capital...,
-
Corp /De/Bristol Myers Squi...,